Eyenovia (EYEN)
(Delayed Data from NSDQ)
$0.74 USD
-0.02 (-3.02%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $0.72 -0.02 (-2.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Eyenovia, Inc. [EYEN]
Reports for Purchase
Showing records 41 - 60 ( 83 total )
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results Reported; Reiterate Buy; Reducing PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Barring COVID-19 Delays, MicroLine Pivotal Data in 4Q20 - Reports 4Q19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Late Stage Assets - Novel Delivery Device for Derisked Products
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroLine (Near-term) and MicroPine (Long-term) the Drivers
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Presbyopia Therapy Development Prioritized; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroPine Phase 3 Study Enrolls the First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
4Q18 Recap - Active Pipeline/ Launches Start in 2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Development Timeline Update; Commercialization Strategy Outlined; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroStat MIST-2 Confirmatory Phase 3 Study Reports Positive Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R